Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool

Tina Shahani, Renaud Lavend'homme, Aernout Luttun, Jean-Marie Saint-Remy, Kathelijne Peerlinck, Marc Jacquemin

Blood (2010) 115 (23): 4902–4909.

https://doi.org/10.1182/blood-2009-07-232546

Published: 2010

Includes: Supplemental data

Journal Articles

Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity.

Peter Verhamme, MD, PhD, Steve Pakola, MD, Marc Jacquemin, MD, PhD, Jean Marie Saint-Remy, MD, PhD, Jean Marie Stassen, PhD, Desire Collen, MD, PhD, Rikke Riisbro, MD, PhD, Thomas Jensen, MD, PhD, Steven Glazer, MD

Blood (2007) 110 (11): 312.

https://doi.org/10.1182/blood.V110.11.312.312

Published: 2007

Journal Articles

Immune Tolerance Induction by High Doses FVIII in Hemophilia A Patients with Inhibitor Does Not Require Deletion of FVIII-Specific T Cells.

Marc G. Jacquemin, MD, Renaud Lavend’homme, Ms, Thérèse Tinot, Ms, Kathelijne Peerlinck, MD, Jean Marie Saint-Remy, MD, Brigitte Pautard, MD

Blood (2006) 108 (11): 1029.

https://doi.org/10.1182/blood.V108.11.1029.1029

Published: 2006

Journal Articles

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors

Suryasarathi Dasgupta, Yohann Repessé, Jagadeesh Bayry, Ana-Maria Navarrete, Bharath Wootla, Sandrine Delignat, Theano Irinopoulou, Caroline Kamaté, Jean-Marie Saint-Remy, Marc Jacquemin, Peter J. Lenting, Annie Borel-Derlon, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes

Blood (2006) 109 (2): 610–612.

https://doi.org/10.1182/blood-2006-05-022756

Published: 2006

Includes: Supplemental data

Journal Articles

FVIII production by human lung microvascular endothelial cells

Marc Jacquemin, Arne Neyrinck, Maria Iris Hermanns, Renaud Lavend'homme, Filip Rega, Jean-Marie Saint-Remy, Kathelijne Peerlinck, Dirk Van Raemdonck, Charles James Kirkpatrick

Blood (2006) 108 (2): 515–517.

https://doi.org/10.1182/blood-2005-11-4571

Published: 2006

Journal Articles

The Determination of the Inhibitory Activity of Some Factor VIII Type II Inhibitor Antibodies Is Biased by the Type of Factor VIII Assay.

Marc G. Jacquemin, MD, Seb Lamprecht, MSc, Renaud Lavend’homme, MSc, Jan Roodt, MSc, Bernard Chatelain, MD, Veronique Deneys, MD, Jeroen Dewaele, MSc, Jean-Marie Stassen, PhD, Muriel Meiring, PhD, Jean Marie Saint-Remy, MD, Henry Pieters, PhD, Philip Badenhorst, MD

Blood (2005) 106 (11): 3200.

https://doi.org/10.1182/blood.V106.11.3200.3200

Published: 2005

Journal Articles

Rupture of T Cell Tolerance to Self Factor VIII in Mild/Moderate Hemophilia A.

Marc G. Jacquemin, MD, PhD, Renaud Lavend’homme, Ms, Benhida Abdellah, Kathelijne Peerlinck, MD, PhD, Jos Vermylen, MD, PhD, Véronique Deneys, MD, PhD, Jean-Marie Saint-Remy, MD, PhD, Cédric Hermans, MD, PhD

Blood (2004) 104 (11): 3076.

https://doi.org/10.1182/blood.V104.11.3076.3076

Published: 2004

Journal Articles

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

Roseline d'Oiron, Jean-Maurice Lavergne, Renaud Lavend'homme, Abdellah Benhida, Jean-Claude Bordet, Claude Negrier, Kathelijne Peerlinck, Jos Vermylen, Jean-Marie Saint-Remy, Marc Jacquemin

Blood (2004) 103 (1): 155–157.

https://doi.org/10.1182/blood-2003-04-1321

Published: 2004

Journal Articles

Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor

Sylvie Villard, Sébastien Lacroix-Desmazes, Thomas Kieber-Emmons, Dominique Piquer, Sabrina Grailly, Abdellah Benhida, Srini V. Kaveri, Jean-Marie Saint-Remy, Claude Granier

Blood (2003) 102 (3): 949–952.

https://doi.org/10.1182/blood-2002-06-1886

Published: 2003

Journal Articles

CD4 + T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A

Marc Jacquemin, Valérie Vantomme, Cécile Buhot, Renaud Lavend'homme, Wivine Burny, Nathalie Demotte, Pascal Chaux, Kathelijne Peerlinck, Jos Vermylen, Bernard Maillere, Pierre van der Bruggen, Jean-Marie Saint-Remy

Blood (2003) 101 (4): 1351–1358.

https://doi.org/10.1182/blood-2002-05-1369

Published: 2003

Journal Articles

Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model

Inderjit Singh, Alberto Smith, Beatrijs Vanzieleghem, Désiré Collen, Kevin Burnand, Jean-Marie Saint-Remy, Marc Jacquemin

Blood (2002) 99 (9): 3235–3240.

https://doi.org/10.1182/blood.V99.9.3235

Published: 2002

Journal Articles

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor

Marc Jacquemin, Abdellah Benhida, Kathelijne Peerlinck, Benoı̂t Desqueper, Luc Vander Elst, Renaud Lavend'homme, Roseline d'Oiron, Rainer Schwaab, Marleen Bakkus, Kris Thielemans, Jean-Guy Gilles, Jos Vermylen, Jean-Marie Saint-Remy

Blood (2000) 95 (1): 156–163.

https://doi.org/10.1182/blood.V95.1.156

Published: 2000

NARROW

Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool

Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity.

Immune Tolerance Induction by High Doses FVIII in Hemophilia A Patients with Inhibitor Does Not Require Deletion of FVIII-Specific T Cells.

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors

FVIII production by human lung microvascular endothelial cells

The Determination of the Inhibitory Activity of Some Factor VIII Type II Inhibitor Antibodies Is Biased by the Type of Factor VIII Assay.

Rupture of T Cell Tolerance to Self Factor VIII in Mild/Moderate Hemophilia A.

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor

CD4 + T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A

Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only